Elevation of Intracellular Glucosylceramide Levels Results ... - CiteSeerX

0 downloads 0 Views 323KB Size Report
Gaucher disease is a glycosphingolipid storage dis- ease caused by defects in the activity of the lysosomal hydrolase, glucocerebrosidase (GlcCerase) ...
THE JOURNAL OF BIOLOGICAL CHEMISTRY © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

Vol. 274, No. 31, Issue of July 30, pp. 21673–21678, 1999 Printed in U.S.A.

Elevation of Intracellular Glucosylceramide Levels Results in an Increase in Endoplasmic Reticulum Density and in Functional Calcium Stores in Cultured Neurons* (Received for publication, December 10, 1998, and in revised form, April 8, 1999)

Eduard Korkotian‡§, Andreas Schwarz§¶, Dori Pelled¶, Gu ¨ nter Schwarzmanni, Menahem Segal‡, and Anthony H. Futerman¶** From the Departments of ‡Neurobiology and ¶Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel and the iKekule´-Institut fu¨r Organische Chemie und Biochemie, Universitat Bonn, Bonn 53121, Germany

Glucosylceramide (GlcCer),1 a degradation product of complex glycosphingolipids (GSLs), is hydrolyzed in lysosomes by * This work was supported by the Mizutani Foundation for Glycoscience and the Minna James Heineman Foundation (to A. H. F.) and by the Deutsche Forschungsgemeinschaft (to G. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. § Both authors contributed equally to the work. ** To whom correspondence should be addressed. Tel.: 972-89342704; Fax: 972-8-9344112; E-mail: [email protected]. ac.il. 1 The abbreviations used are: GlcCer, glucosylceramide; CBE, conduritol-B-epoxide; DiO, 3,39-dihexyloxacarbocyanine iodide; ER, endoplasmic reticulum; FB1, fumonisin B1; GlcCerase, glucocerebrosidase; C8-Glc-S-Cer, C8-glucosylthioceramide; C5-DMB-GlcCer, N-[5-(5, 7dimethyl bodipy)-1-pentanoyl]-D-erythro-glucosylsphingosine; GSL, glycosphingolipid; RR, ryanodine receptor. This paper is available on line at http://www.jbc.org

the acid hydrolase, glucocerebrosidase (D-glucosylacylsphingosine glucohydrolase; GlcCerase). Mutations in the human GlcCerase gene cause a reduction in GlcCerase activity and accumulation of GlcCer, which results in Gaucher disease, the most common lysosomal storage disease (1). As for all lysosomal storage diseases, significant clinical heterogeneity is observed in Gaucher disease, with three main types known, varying from a chronic non-neuronopathic type (type 1) to infantile (type 2) and juvenile (type 3) neuronopathic types (2). The acute neuronopathic type of the disease is characterized by severe loss of neurons in the central nervous system and early onset of the disease (1). A molecular explanation for the neuronal dysfunction associated with neuronopathic forms of Gaucher disease is currently lacking, and no neurotoxic agent has been identified. In the current study, we have analyzed the effects of treating cultured hippocampal neurons with an active site-directed inhibitor of GlcCerase, conduritol-B-epoxide (CBE) (3). We previously demonstrated that GlcCer accumulates in neurons upon CBE treatment, resulting in changes in axonal morphology, with an increase in the length of the axon plexus and in the number of axonal branch points per cell (4), although CBE had no effect on dendrite development (5). Co-incubation with CBE and inhibitors of sphingolipid synthesis (i.e. fumonisin B1 (FB1), an inhibitor of acylation of sphingoid long-chain bases (6)), antagonizes the effects of CBE, and FB1 itself reduces the rate of axonal growth (4, 7, 8). We now demonstrate that in addition to these morphological changes, GlcCer accumulation causes changes in neuronal functionality, inasmuch as neurons show increased levels of tubular endoplasmic reticulum (ER) elements, a large increase in [Ca21]i release from the ER in response to glutamate or caffeine stimulation, and are more sensitive to glutamate-induced neurotoxicity. This is the first time that changes in neuronal functionality have been reported in neurons with elevated GlcCer levels and may help unravel the mechanisms that lead to neuronopathic forms of Gaucher disease. EXPERIMENTAL PROCEDURES

Hippocampal Cultures—Hippocampal neurons were cultured on poly-L-lysine-coated glass coverslips essentially as described (4, 9). Briefly, the dissected hippocampi of embryonic day 18 rats (Wistar), obtained from the Weizmann Institute Breeding Center, were dissociated by trypsinization (0.25% w/v, for 15 min at 37 °C). The tissue was washed in Mg21/Ca21-free Hank’s balanced salt solution (Life Technologies, Inc.) and dissociated by repeated passage through a constricted Pasteur pipette. For biochemical analysis, cells were plated in minimal essential medium with 10% horse serum at a density of 240,000 cells/ 24-mm poly-L-lysine-coated glass coverslip. For morphological analysis, neurons were plated at a density of 6,000 cells/13-mm coverslip. After 3– 4 h, coverslips were transferred into 100-mm Petri dishes or 24-well Multidishes that contained a monolayer of astroglia. Coverslips were

21673

Downloaded from www.jbc.org at Weizmann Institute of Science on January 30, 2007

Gaucher disease is a glycosphingolipid storage disease caused by defects in the activity of the lysosomal hydrolase, glucocerebrosidase (GlcCerase), resulting in accumulation of glucocerebroside (glucosylceramide, GlcCer) in lysosomes. The acute neuronopathic type of the disease is characterized by severe loss of neurons in the central nervous system, suggesting that a neurotoxic agent might be responsible for cellular disruption and neuronal death. We now demonstrate that upon incubation with a chemical inhibitor of GlcCerase, conduritol-B-epoxide (CBE), cultured hippocampal neurons accumulate GlcCer. Surprisingly, increased levels of tubular endoplasmic reticulum elements, an increase in [Ca21]i response to glutamate, and a large increase in [Ca21]i release from the endoplasmic reticulum in response to caffeine were detected in these cells. There was a direct relationship between these effects and GlcCer accumulation since co-incubation with CBE and an inhibitor of glycosphingolipid synthesis, fumonisin B1, completely antagonized the effects of CBE. Similar effects on endoplasmic reticulum morphology and [Ca21]i stores were observed upon incubation with a short-acyl chain, nonhydrolyzable analogue of GlcCer, C8-glucosylthioceramide. Finally, neurons with elevated GlcCer levels were much more sensitive to the neurotoxic effects of high concentrations of glutamate than control cells; moreover, this enhanced toxicity was blocked by pre-incubation with ryanodine, suggesting that [Ca21]i release from ryanodine-sensitive intracellular stores can induce neuronal cell death, at least in neurons with elevated GlcCer levels. These results may provide a molecular mechanism to explain neuronal dysfunction and cell death in neuronopathic forms of Gaucher disease.

21674

Glucocerebroside Accumulation and Neuronal Calcium Stores

TABLE I [3H]GSL accumulation after treatment of neurons with CBE Neurons cultured at high density were incubated with 5 3 106 cpm of [3H]dihydrosphingosine for 6 h immediately after plating and subsequently incubated with or without 200 mM CBE on day 1 in culture. After 4 and 9 days, [3H]GSLs were extracted and analyzed. Lipida

Control (day 4)

CBE-treated (day 4)

GT1b GD1b GD1a GD3 GM1 GM2 GM3 SM LacCer GlcCer Cer

15878 6 2233 10576 6 3006 10988 6 1020 11522 6 2448 4014 6 699 1108 6 180 4914 6 1249 5748 6 3441 2299 6 368 1412 6 468 2331 6 731

13227 6 1737 10214 6 3240 10360 6 1288 12902 6 2585 4271 6 390 1757 6 131 6069 6 1475 5397 6 3365 2524 6 854 5616 6 1670 2073 6 952

-Fold change (day 4)

Control (day 9)

CBE-treated (day 9)

-Fold change (day 9)

13718 6 3017 9938 6 2902 10498 6 2862 12580 6 5172 5702 6 1870 2998 6 1449 6350 6 2246 3364 6 1788 3607 6 845 12555 6 5937 7248 6 2616

0.76 0.86 0.81 1.13 0.99 1.19 1.25 0.71 1.09 5.51 0.88

[3H]GSLs and [3H]ceramide (cpm)

a

0.80 0.90 0.87 1.17 1.08 1.53 1.20 0.81 0.96 4.84 0.95

18292 6 4883 11712 6 3810 13248 6 4431 10884 6 3824 5980 6 2428 2557 6 1298 5417 6 2515 4668 6 2392 4168 6 2312 2212 6 920 8195 6 2832

Gangliosides are named according to Svennerholm (46). SM, sphingomyelin; LacCer, lactosylceramide; Cer, ceramide.

placed with the neurons facing downwards and were separated from the glia by paraffin “feet.” Cultures were maintained in serum-free minimal essential medium that included N2 supplements (9), ovalbumin (0.1%, w/v), and pyruvate (0.1 mM). Incubation with Lipids and Inhibitors—Neuronal cultures were incubated with CBE (200 mM) or FB1 (50 mM) prepared as stock solutions in 20 mM Hepes buffer, pH 7.4 (4, 10) or with C8-glucosylthioceramide (C8-Glc-S-Cer) (5 mM) (11) prepared as a stock solution in ethanol. The intracellular distribution of N-[5-(5, 7-dimethylbodipy)-1-pentanoyl]-Derythro-glucosylsphingosine (C5-DMB-GlcCer) was determined by incubating neurons for 24 h at 37 °C with C5-DMB-GlcCer, prepared as an equimolar complex with defatted bovine serum albumin (12), prior to removal of cell surface-associated C5-DMB-GlcCer by incubating cells for 4 3 10 min with bovine serum albumin (1% w/v) at 16 °C (“backexchange” (12)). The intracellular distribution of a fluorescent derivative of C8-Glc-S-Cer, C8-NBD-Glc-S-Cer (13), was determined similarly. Neurons were examined using a Plan Apochromat 403/1.3 oil objective of a Zeiss Axiovert 35 microscope with an appropriate fluorescence filter. Lipid Analysis—Neurons cultured at high density were incubated with 5 3 106 cpm of [3H]dihydrosphingosine (10 Ci/mmol) (14) for 6 h immediately after plating. After various times, [3H]GSLs were extracted and analyzed (15), and levels of [3H]sphingolipids and [3H]GSLs were quantified. Upon metabolism of [4,5-3H]dihydroceramide to [3H]ceramide, we assume that 50% of the 3H-labeled radioactivity is lost because of dehydrogenation of the 4,5-double bond; this was taken into account when quantifying [3H]GSL synthesis, as described previously (15). ER Labeling—The ER was labeled in live or fixed cells with 3,39dihexyloxacarbocyanine iodide (DiO) (16, 17). The dye was applied at a final concentration of 0.25 mg/ml for 3–5 min to living cells and for 10 min to fixed cells and then was washed extensively. Fluorescence intensities for different groups of fixed cells were collected and averaged. Single optical sections at the Z axes distance of 1 mm were taken, and cells were three-dimensional reconstructed. Immunofluorescence localization of the ryanodine receptor (RR) was performed by incubating fixed cells (4% formaldehyde) with an anti-RR antibody (provided by Dr.

V. Shoshan-Barmatz, Ben Gurion University, Israel) that cross-reacts with both skeletal muscle and brain RR (18). Cells were imaged by confocal microscopy (see below). Fluorescence intensities for both DiO and RR were quantified by analyzing total cell body fluorescence using NIH Image software. Calcium Imaging—3–7-day-old cultures were washed and incubated at room temperature for 1 h with 3 mM fluo-3 AM (Molecular Probes) in recording medium (129 mM NaCl, 4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 4.2 mM glucose, 10 mM Hepes, pH 7.4, and 0.5 mM tetradotoxin, with osmolarity adjusted to 320 mosM by addition of sucrose). Neurons were washed in recording medium and placed on the stage of a confocal laser scanning microscope (Leica, Heidelberg) and superfused with the recording medium at a rate of 3–5 ml/min at room temperature. Glutamate (0.1 mM) or caffeine (5–10 mM) was prepared in recording medium and applied through a pressure pipette with a tip diameter of 2 mm, placed approximately 50 mm from the cells. Averages of 4 images per second were stored for later analysis. Laser light intensity was set to 5% of the maximum. Images were analyzed with Leica and NIH Image software. Glutamate Neurotoxicity—Neurons (plated at a density of 25,000 cells/well) were incubated with various inhibitors or lipids for 4 days, prior to application of 10 mM glutamate for 1 h. Live and dead cells were distinguished using 2 mM calcein acetoxymethyl ester and 4 mM ethidium homodimer-1, respectively, as described in a Live/Dead® viability/cytotoxicity kit (Molecular Probes). In some experiments, neurons were pre-treated with ryanodine for 1 h prior to application of glutamate. 45 Ca21 Uptake—Neurons (plated at a density of 100,00 cells/well) were incubated with or without 200 mM CBE for 4 days. Coverslips were then washed in Ca21-free medium (minimal essential medium containing 50 mM Hepes (pH 7.3), 4 mM NaHCO3, 11 mg/ml pyruvic acid, 1 mM glutamine, and 0.6% (w/v) glucose (19)), and transferred to a new multi-well dish containing the same medium but not containing a glia monolayer. After 25 min at 37 °C, neurons were incubated with the calcium ionophore A23187 (1 mM) (20), and in some cases with thapsigargin (0.1 mM) (an inhibitor of Ca21 uptake into the ER (21)), for 5 min,

Downloaded from www.jbc.org at Weizmann Institute of Science on January 30, 2007

FIG. 1. Lysosomal accumulation of GlcCer in CBE-treated neurons. a, [3H]GlcCer accumulation was analyzed on different days in culture after incubation with (E) or without (f) CBE (200 mM), as described for Table I. b, neurons cultured at low density were treated with CBE immediately after plating and incubated with C5-DMB-GlcCer on day 2 for 24 h. Top panels, phase-contrast micrographs; bottom panels, immunofluorescence. Bar 5 10 mm.

Glucocerebroside Accumulation and Neuronal Calcium Stores

21675

FIG. 4. [Ca21]i release from the ER in response to glutamate. Glutamate (1 mM) was applied to 3–5 day-old neurons via a pressure pipette (50 msec pulse), and the change in fluo-3 fluorescence was measured in control (E) (n 5 15), CBE-treated (●) (n 5 17), and FB1-treated cells (L) (n 5 15). DF/F is the change in fluorescence (F) intensity divided by basal fluorescence. Results are means 6 S.E. The response of CBE-treated cells to glutamate was statistically larger than the response of control cells. FIG. 3. Quantification of ER-labeling. Neurons were incubated with CBE, CBE and FB1, or GSC (C8-Glc-S-Cer), from days 0 – 4 in culture, and images were collected as in Fig. 2. Average fluorescent intensities, quantified for at least 20 cells for each treatment, are shown for DiO-labeled (a) and for RR-labeled neurons (b). prior to addition of 1 mCi 45Ca21 (18.8 mCi/mg, Amersham Pharmacia Biotech, UK) for various times at 37 °C (22). The reaction was terminated by removing coverslips from the wells, washed by dipping five times in medium, and then adding 0.65 ml of NaOH (0.5 M) for 3 h. 45 Ca21 was quantitatively extracted by adding NaOH for 16 h and then for another 2 h. NaOH extracts were pooled and, 45Ca21 were determined by liquid scintillation counting. RESULTS

Accumulation and Localization of GlcCer—Incubation with CBE results in accumulation of GlcCer in cultured hippocampal neurons (4) and in neuroblastoma cells (23, 24). In hippocampal neurons, a correlation was observed between the extent of inhibition of GlcCer degradation after a 3-day incu-

bation with CBE and the changes in axonal branching patterns (4). To quantify GlcCer accumulation after longer times of incubation with CBE, hippocampal neurons were metabolically labeled with [3H]dihydrosphingosine (14), a precursor of GSLs (15). After 4 and 9 days, there were 4.8- and 5.5-fold increases, respectively, in [3H]GlcCer levels in CBE-treated neurons compared with control cells (Table I) and a 7-fold increase after a 14-day incubation (Fig. 1a). However, there were no significant changes in levels of other GSLs (15) or of lactosylceramide, ceramide, or sphingomyelin (Table I). To determine the intracellular site of GlcCer accumulation after CBE-treatment, neurons were incubated with a short acyl chain fluorescent derivative of GlcCer, C5-DMB-GlcCer (12). In CBE-treated neurons, C5-DMB-GlcCer accumulated mainly in lysosomes, which appear as discrete puncta located in the perikarya and dendrites (Fig. 1b), as observed in previous studies in hippocampal neurons using short acyl chain fluores-

Downloaded from www.jbc.org at Weizmann Institute of Science on January 30, 2007

FIG. 2. ER morphology. Neurons were incubated with CBE from days 0 – 4 in culture prior to observation by confocal microscopy and three-dimensional reconstruction of cell images. a and b, DiOlabeling; c and d, immunolocalization of RR. Control cells are shown in panels a and c, and CBE-treated cells are shown in panels b and d. Bar 5 10 mm.

21676

Glucocerebroside Accumulation and Neuronal Calcium Stores

cent GSL analogues (19). In control cells, C5-DMB-GlcCer was extensively hydrolyzed to C5-DMB-ceramide during a 24-h incubation (not shown), as observed in nonneuronal cells (12, 25), and accumulated in the Golgi apparatus (Fig. 1b), which has a perinuclear location at this developmental stage (26). Effects of GlcCer Accumulation on ER Morphology—We next examined the intracellular morphology of neurons treated with CBE for various times in culture. Upon incubation with DiO, a generic marker of the ER (16, 17), CBE-treated neurons showed significantly more tubular ER elements (Fig. 2, a and b). No nuclear labeling was observed, but the density of labeling of ER elements above the nucleus was significantly higher in CBEtreated cells (Fig. 2b), resulting in a marked (;3-fold) increase in ER density compared with untreated cells (Fig. 3a). No effects on ER morphology were observed upon incubation with FB1, but the increased levels of DiO-labeling of the ER induced by CBE was blocked by co-incubation with CBE and FB1 (Fig. 3a). The increase in ER density was confirmed using an antibody to the RR, a calcium channel located in the ER of hippocampal neurons (27). Incubation with either CBE or with a nonhydrolyzable analogue of GlcCer (C8-Glc-S-Cer) (11, 13), resulted in an increase in RR labeling in a perinuclear region of the neurons, corresponding to the ER (Fig. 2, c and d). Quantification of labeling intensity demonstrated an ;2-fold increase in RR density on the ER after incubation with either CBE or C8-GlcS-Cer (Fig. 3b). Moreover, preliminary analysis by electron microscopy revealed an increase in the surface density of the ER in CBE-treated neurons after a 5-day incubation (3.29 6 0.98 ER intersections per mm test line in control cells compared with 4.79 6 1.29 ER intersections per mm test line in CBEtreated neurons).2 Effects of GlcCer Accumulation on [Ca21]i Release from the ER—We next examined the functionality of increased levels of ER elements and of the RR. Initially, the responses of control 2

H. Shogomori and A. H. Futerman, unpublished observations.

and CBE-treated cells to glutamate were examined. Following a pulsed application of glutamate, there was a typical increase in fluo-3 AM fluorescence that peaked after about 2–3 s and decayed back to control levels within 15–20 s (Fig. 4), as previously observed (16). In CBE-treated cells, the peak response to glutamate was 63% larger than that of control cells (Fig. 4). To examine if this larger response to glutamate is related to changes in calcium stores, we used caffeine, a more selective releaser of calcium from stores (27). Caffeine caused a transient increase in free [Ca21]i (Fig. 5, a and b), which recovered back to base-line levels within 10 –20 s in control cells (Fig. 6). A 3-fold increase in the magnitude of the [Ca21]i response to caffeine was recorded in cells incubated with CBE for 4 days (Figs. 5, c and d, and Fig. 6) or with C8-Glc-S-Cer for 4 days (Fig. 6), with a marked increase in both the peak and duration of the response; similar data were obtained using a ratiometric dye, Fura-2 (not shown). The response was totally blocked upon co-incubation with CBE and FB1, which reduced [Ca21]i changes to below levels of the control response (Fig. 6). As previously observed in control cells (16, 27), the response of CBE-treated cells to caffeine was blocked in the presence of ryanodine (not shown). No effects were observed on caffeinestimulated [Ca21]i release after short-term incubation (12 h) with either CBE or C8-Glc-S-Cer. To examine the functional consequences of the increase in caffeine-sensitive calcium stores and the increased response to glutamate, the sensitivity of neurons to glutamate toxicity (10 mM, 1 h) was examined. Neurons incubated with either CBE or C8-Glc-S-Cer were much more sensitive than control cells to glutamate-induced neuronal cell death, and this effect was abolished by co-incubation with CBE and FB1 (Fig. 7a). Remarkably, pre-incubation with ryanodine for 1 h completely blocked the neurotoxic effects of glutamate in a dose-dependent manner (Fig. 7b), demonstrating that the release of Ca21 from the ER is responsible for glutamate-induced neuronal cell death, at least in neurons with elevated GlcCer levels.

Downloaded from www.jbc.org at Weizmann Institute of Science on January 30, 2007

FIG. 5. [Ca21]i release from the ER in response to caffeine. Neurons were incubated with CBE for 4 days prior to analysis of transient [Ca21]i release from the ER following exposure of cells to a pulsed application of caffeine. Typical responses are shown for a control (a and b) and a CBE-treated cell (c and d) before (a and c) and during the response to caffeine (b and d). There were no differences in the size and shape of neuronal perikarya between treated- and untreated-cells. Bar 5 10 mm.

Glucocerebroside Accumulation and Neuronal Calcium Stores

FIG. 8. Quantification of 45Ca21 uptake into the ER. 45Ca21 uptake into the ER is shown for control neurons (f), CBE-treated neurons (o), and for control neurons treated with thapsigargin for 5 min before incubation with 45Ca21 (u). The average cpm/coverslip for control cells after 20 s was 1804 6 393 and was 7906 6 2167 after 40 s. Protein and protein/cell was estimated based on previous analysis (15, 45), and results are expressed as means of nmol of 45Ca21 per mg of protein 6 S.E. (n 5 12–19 for 20 and 30 s, and n 5 4 for 40 s). 45Ca21 uptake in CBE-treated and control neurons was statistically indistinguishable (Student’s t test) but was significantly different from neurons treated with thapsigargin (p , 0.001).

[Ca21]i influx into the ER in neurons with elevated GlcCer levels (Fig. 8). This suggests that free [Ca21]i is elevated because of increased efflux from the ER, which is consistent with the increase in RR-density on the ER (Fig. 3b), with calculations showing that the rate of increase in free [Ca21]i after caffeine application is proportional to the rate of decrease of free [Ca21]i (Fig. 6) and with the lack of effect of thapsigargin on glutamate toxicity (Fig. 8). DISCUSSION

FIG. 7. Glutamate-induced neurotoxicity. a, glutamate toxicity (10 mM, 1 h) is shown for untreated cells and for cells treated for 4 days with CBE (200 mM), CBE (200 mM) 1 FB1 (10 mM), or Glc-S-Cer (2 mM). Results are means 6 S.E. for 2–21 coverslips per treatment. Note that glutamate had no effect on neuronal cell death in untreated 4-day old neurons since the percent of dead neurons obtained in the absence of glutamate (15.3 6 6.5, n 5 21) was identical to that obtained in its presence (15.9 6 6.1, n 5 21). b, CBE-treated (200 mM, 4 days) neurons were incubated with increasing concentrations of ryanodine for 1 h prior to application of glutamate. The percentage of dead neurons after ryanodine (50 mM) treatment alone (i.e. no glutamate addition) was 15.0 6 2.6 (n 5 4), and the percentage of dead CBE-treated neurons in the absence of glutamate was identical to that of control cells. In contrast to the effects of ryanodine, pre-incubation with thapsigargin (an inhibitor of the ER Ca21ATPase) did not block the neurotoxic effects of glutamate on CBE-treated cells (percent of dead cells after thapsigargin and glutamate 5 37.9 6 10.7, n 5 4, compared with 40.3 6 6.8, n 5 11 for glutamate alone).

Effects of GlcCer accumulation on 45Ca21 Uptake into the ER—To distinguish between the possibilities that changes in cytosolic free [Ca21]i result from altered [Ca21]i efflux from the ER or alternatively from altered [Ca21]i influx, neurons were incubated with 45Ca21 after permeabilization of the plasma membrane using the calcium ionophore, A23187. No difference was observed between control and CBE-treated neurons in the rate or amount of 45Ca21 uptake into the ER after 20, 30, or 40 s, demonstrating that there is no change in the rate of

In the current study, we demonstrate that elevation of intracellular GlcCer levels causes changes in the morphology and functionality of the ER in cultured hippocampal neurons. Although we have not unambiguously demonstrated that these effects are caused by accumulation of GlcCer in lysosomes (rather than accumulation in other intracellular compartments), our observations are of relevance for understanding the neuronal dysfunction and cell death that are observed in neuronopathic forms of Gaucher disease, in which massive lysosomal accumulation of GlcCer occurs (1). Only limited studies on the neuropathology of Gaucher patients exist, but changes in neuronal morphology have been observed, including dilated and distended smooth and rough ER in brains from neuronopathic forms of Gaucher disease (28, 29), and marked dilations of the rough ER in corneal keratinocytes from the neuronopathic form of Gaucher disease (30). Similar morphological findings were observed in the brains of mice fed CBE (31). Even less is known about the relationship between neuronal cell death and accumulation of GlcCer. We now demonstrate, for the first time, a direct relationship between GlcCer accumulation, Ca21 release from intracellular stores, and neuronal cell death. This finding may have implications not only for understanding neuronal cell death in Gaucher disease, but also for the neurotoxic roles of glutamate in other neurodegenerative conditions. Only limited data is available about the levels of GlcCer accumulation in Gaucher patients, and there are no systematic studies comparing levels of accumulation in various brain regions at various stages of progression of the disease. In one study, GlcCer levels were 20 – 80 times higher in the cerebral

Downloaded from www.jbc.org at Weizmann Institute of Science on January 30, 2007

FIG. 6. Quantification of [Ca21]i release. The average response to caffeine of all cells is shown. Results are means 6 S.E. Control (f), n 5 121 cells; CBE-treated (E), n 5 120; FB1-treated (J), n 5 64; CBE and FB1-treated (●), n 5 32; C8-Glc-S-Cer (GSC) (M), n 5 63. DF/F is the change in fluorescence (F) intensity divided by basal fluorescence. There were no changes in basal fluorescence levels before caffeine application (control, 47.75 6 1.96 absolute fluorescence units; CBEtreated, 49.79 6 1.4; FB1-treated, 50.32 6 2.59; CBE and FB1-treated, 48.35 6 3.86; C8-Glc-S-Cer, 48.39 6 1.55), obtained under identical conditions for each treatment. Note that the rate of increase of free [Ca21]i is proportional to the rate of decrease of free [Ca21]i in all experimental conditions: CBE-treated neurons (DF/F per s 5 0.24 for increase, and 0.49 for decrease, ratio 5 0.49); Glc-S-Cer-treated neurons (DF/F per s 5 0.27 for increase and 0.68 for decrease, ratio 5 0.40); control (DF/F per s 5 0.10 and 0.19, ratio 5 0.53); FB1-treated (DF/F per s 5 0.05 and 0.15, ratio 0.33); CBE 1 FB1-treated neurons (DF/F per s 5 0.02 and 0.05, ratio 5 0.40).

21677

21678

Glucocerebroside Accumulation and Neuronal Calcium Stores

Acknowledgment—We thank Dr. V. Shoshan-Barmatz, Ben Gurion University, Israel, for providing the anti-RR antibody.

REFERENCES 1. Beutler, E., and Grabowski, G. A. (1995) in The Metabolic and Molecular Bases of Inherited Diseases (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds), pp. 2641–2670, McGraw-Hill Inc., New York 2. Barranger, J. A., and Ginns, E. I. (1989) Glucosylceramide Lipidoses: Gaucher Disease, 6th Ed., McGraw Hill Inc., New York 3. Legler, G. (1977) Methods Enzymol. 46, 368 –381 4. Schwarz, A., Rapaport, E., Hirschberg, K., and Futerman, A. H. (1995) J. Biol. Chem. 270, 10990 –10998 5. Schwarz, A., and Futerman, A. H. (1998) Brain Res. Dev. Brain Res. 108, 125–130 6. Merrill, A. H., Liotta, D. C., and Riley, R. (1996) Trends Cell Biol. 6, 218 –223 7. Harel, R., and Futerman, A. H. (1993) J. Biol. Chem. 268, 14476 –14481 8. Boldin, S., and Futerman, A. H. (1997) J. Neurochem. 68, 882– 885 9. Goslin, K., Asmussen, H., and Banker, G. (1998) in Culturing Nerve Cells (Banker, G., and Goslin, K., eds) pp. 339 –370, MIT Press, Cambridge, MA 10. Schwarz, A., and Futerman, A. H. (1997) J. Neurosci. 17, 2929 –2938 11. Schwarzmann, G., Hofmann, P., Pu¨tz, T., and Albrecht, B. (1995) J. Biol. Chem. 270, 21271–21276 12. Martin, O. C., and Pagano, R. E. (1994) J. Cell Biol. 125, 769 –781 13. Albrecht, B., Pu¨tz, U., and Schwarzmann, G. (1995) Carbohydr. Res. 276, 289 –308 14. Hirschberg, K., Rodger, J., and Futerman, A. H. (1993) Biochem. J. 290, 751–757 15. Hirschberg, K., Zisling, R., van Echten-Deckert, G., and Futerman, A. H. (1996) J. Biol. Chem. 271, 14876 –14882 16. Korkotian, E., and Segal, M. (1997) J. Neurosci. 17, 1670 –1682 17. Lee, C., and Chen, L. B. (1988) Cell 54, 37– 46 18. Shoshan-Barmatz, V., and Ashley, R. H. (1998) Int. Rev. Cytol. 183, 185–270 19. Sofer, A., Schwarzmann, G., and Futerman, A. H. (1996) J. Cell Sci. 109, 2111–2119 20. Deber, C. M., and Hsu, L. C. (1986) Biochem. Biophys. Res. Commun. 134, 731–735 21. Wells, K. M., and Abercrombie, R. F. (1998) J. Biol. Chem. 273, 5020 –5025 22. Fields, A., Gafni, Y., Oron, Y., and Sarne, Y. (1995) Brain Res. 687, 94 –102 23. Prence, E. M., Chaturvedi, P., and Newburg, D. S. (1996) J. Neurosci. Res. 43, 365–371 24. Bierberich, E., Freischutz, B., Suzuki, M., and Yu, R. K. (1999) J. Neurochem. 72, 1040 –1049 25. Pagano, R. E., Martin, O. C., Kang, H. C., and Haugland, R. P. (1991) J. Cell Biol. 113, 1267–1279 26. Sofer, A., and Futerman, A. H. (1995) J. Biol. Chem. 270, 12117–12122 27. Korkotian, E., and Segal, M. (1998) Eur. J. Neurosci. 10, 2076 –2084 28. Adachi, M., Wallace, B. J., Schneck, L., and Volk, B. W. (1967) Arch. Pathol. 83, 513–526 29. Cervos Navarro, J., and Zimmer, C. (1990) Clin. Neuropathol. 9, 310 –313 30. Salgado Borges, J., Silva Araujo, A., Lemos, M. M., Sa Miranda, M. C., Abreu Dias, P., and Tavares, M. A. (1995) Eur. J. Ophthalmol. 5, 69 –74 31. Adachi, M., and Volk, B. W. (1977) Arch. Pathol. Lab. Med. 101, 255–259 32. Nilsson, O., and Svennerholm, L. (1982) J. Neurochem. 39, 709 –718 33. Kaye, E. M., Ullman, M. D., Wilson, E. R., and Barranger, J. A. (1986) Ann. Neurol. 20, 223–230 34. Meivar-Levy, I., Horowitz, M., and Futerman, A. H. (1994) Biochem. J. 303, 377–382 35. Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., Winchester, B., Dwek, R. A., and Butters, T. D. (1997) Science 276, 428 – 431 36. Trinchera, M., Carretoni, D., and Ghidoni, R. (1991) J. Biol. Chem. 266, 9093–9099 37. Futerman, A. H. (1998) Biochemistry (Moscow) 63, 74 – 83 38. Betto, R., Teresi, A., Turcato, F., Salviati, G., Sabbadini, R. A., Krown, K., Glembotski, C. C., Kindman, L. A., Dettbarn, C., Pereon, Y., Yasui, K., and Palade, P. T. (1997) Biochem. J. 322, 327–333 39. Furuya, S., Kurono, S., and Hirabayashi, Y. (1996) J. Lipid Mediat. Cell Signal. 14, 303–311 40. Ghosh, T. K., Bian, J., and Gill, D. L. (1990) Science 248, 1653–1656 41. Mattie, M., Brooker, G., and Spiegel, S. (1994) J. Biol. Chem. 269, 3181–3188 42. Dyer, C. A., and Benjamins, J. A. (1991) J. Neurosci. Res. 30, 699 –711 43. Mahdiyoun, S., Deshmukh, G. D., Abe, A., Radin, N. S., and Shayman, J. A. (1992) Arch. Biochem. Biophys. 292, 506 –511 44. Shayman, J. A., Mahdiyoun, S., Deshmukh, G., Barcelon, F., Inokuchi, J., and Radin, N. S. (1990) J. Biol. Chem. 265, 12135–12138 45. Samuel, N., Wonnacott, S., Lindstrom, J., and Futerman, A. H. (1997) Neurosci. Lett. 222, 179 –182 46. Svennerholm, L. (1963) J. Neurochem. 10, 613– 623

Downloaded from www.jbc.org at Weizmann Institute of Science on January 30, 2007

cortex from a type 2 Gaucher patient and 5– 40 times higher in the cerebellar cortex (32). In another study (33), GlcCer levels were elevated in both type 2 and 3 patients, but neuropathological findings were detected only in the type 2 brain. At this stage, we are unable to correlate levels of GlcCer accumulation in cultured neurons with the extent of neuronal dysfunction, but analysis of GlcCer accumulation (or the extent GlcCerase inhibition (34)) and changes in ER function, including [Ca21]i release from the ER, are currently underway. We have repeated most of the findings obtained using CBE with a nonhydrolyzable analogue of GlcCer, C8-Glc-S-Cer, to confirm that the effects of CBE are indeed because of GlcCer accumulation and not because of a nonselective, pharmacological action of CBE. This is further confirmed by studies in which accumulation of GlcCer was prevented by co-incubation with FB1 and CBE. Using a similar approach, the accumulation of ganglioside GM2 was blocked in Tay-Sachs mice treated with an inhibitor of GlcCer synthesis (35). Thus, treatment of patients suffering from a sphingolipid storage disorder with inhibitors of sphingolipid synthesis may yet prove to be a viable therapeutic option. There are two possibilities as to how intracellular accumulation of GlcCer could affect ER morphology and Ca21 stores. First, GlcCer could directly affect the ER. In this scenario, GlcCer would need to be transported from its site of accumulation (in lysosomes and perhaps other organelles) to the ER. Both short acyl-chain analogues of GlcCer (11, 12), and also metabolically labeled GlcCer (36) can be transported out of endosomes and lysosomes and accumulate in the intracellular compartments (the ER and Golgi apparatus) where they are metabolized to higher order sphingolipids (11, 37). In hippocampal neurons, a fluorescent derivative of C8-Glc-S-Cer, C8-NBD-Glc-S-Cer, is internalized to various intracellular compartments, including lysosomes, but also the ER (data not shown). Whether GlcCer accumulation in the ER can alter the activity of ER Ca21 channels is unknown, but modulatory effects of lyso-sphingolipids (38, 39), sphingoid long-chain bases (40), metabolites of sphingoid bases (41), and cerebrosides (42) on Ca21 mobilization have been observed. Alternatively, GlcCer could act indirectly on the ER, for instance, by altering levels of an intracellular signaling molecule. Incubation of Madin-Darby Canine Kidney cells with CBE results in decreased bradykinin-stimulated formation of inositol trisphosphate, whereas the opposite effect is observed upon inhibition of GlcCer synthesis (43, 44). Thus, when GlcCer accumulates, inositol trisphosphate levels may be chronically depleted, resulting in up-regulation of the RR in the ER that may in turn be responsible for increased Ca21 release from the ER. Irrespective of the mechanism of action of GlcCer, this is the first time that changes in the functionality of neurons with elevated GlcCer levels have been observed and will provide the experimental tools for analyzing the relationship between GlcCer accumulation and neuronal functionality and development.